The immune system has evolved complex effector mechanisms to protect the host against a
diversity of pathogenic organisms and regulatory adaptations that can curtail pathological …

Although immune-based therapy is proving to be a success in several cancer types, only a
set of patients appear to respond to immune checkpoint blockade including PD-1 and CTLA …

Abstract Forkheadbox protein 3 (FOXP3), initially identified as a key transcription factor for
regulatory T cells (Treg cells), was also expressed in many tumors including pancreatic …

Colorectal cancer (CRC) is a heterogeneous disease with one of the highest rates of
incidence and mortality among cancers worldwide. Understanding the CRC tumor …

Accumulation of myeloid-derived suppressor cells (MDSC) in melanoma microenvironment
is supported by chemokine receptor/chemokine signaling. Although different chemokines …

The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have
been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10 …

Simple Summary The immune response against cancer is generated by effector T cells,
among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that …

The frequency of circulating or tumour‐infiltrating regulatory T cells (Tregs) has been
associated with poor patient survival in many cancers including breast, melanoma and lung …

Regulatory T cells (Tregs) are essential for maintaining peripheral tolerance, preventing
autoimmune diseases and limiting chronic inflammatory diseases. Depletion of Tregs results …

Many patients with chronic inflammation of the gut, such as that observed in inflammatory
bowel disease (IBD), develop colorectal cancer (CRC). Recent studies have reported that …